前往化源商城

Embo Molecular Medicine 2014-01-01

Molecular pathogenesis of spondylocheirodysplastic Ehlers-Danlos syndrome caused by mutant ZIP13 proteins.

Bum-Ho Bin, Shintaro Hojyo, Toshiaki Hosaka, Jinhyuk Bhin, Hiroki Kano, Tomohiro Miyai, Mariko Ikeda, Tomomi Kimura-Someya, Mikako Shirouzu, Eun-Gyung Cho, Kazuhisa Fukue, Taiho Kambe, Wakana Ohashi, Kyu-Han Kim, Juyeon Seo, Dong-Hwa Choi, Yeon-Ju Nam, Daehee Hwang, Ayako Fukunaka, Yoshio Fujitani, Shigeyuki Yokoyama, Andrea Superti-Furga, Shiro Ikegawa, Tae Ryong Lee, Toshiyuki Fukada

文献索引:EMBO Mol. Med. 6(8) , 1028-42, (2014)

全文:HTML全文

摘要

The zinc transporter protein ZIP13 plays critical roles in bone, tooth, and connective tissue development, and its dysfunction is responsible for the spondylocheirodysplastic form of Ehlers-Danlos syndrome (SCD-EDS, OMIM 612350). Here, we report the molecular pathogenic mechanism of SCD-EDS caused by two different mutant ZIP13 proteins found in human patients: ZIP13(G64D), in which Gly at amino acid position 64 is replaced by Asp, and ZIP13(ΔFLA), which contains a deletion of Phe-Leu-Ala. We demonstrated that both the ZIP13(G64D) and ZIP13(ΔFLA) protein levels are decreased by degradation via the valosin-containing protein (VCP)-linked ubiquitin proteasome pathway. The inhibition of degradation pathways rescued the protein expression levels, resulting in improved intracellular Zn homeostasis. Our findings uncover the pathogenic mechanisms elicited by mutant ZIP13 proteins. Further elucidation of these degradation processes may lead to novel therapeutic targets for SCD-EDS. © 2014 The Authors. Published under the terms of the CC BY 4.0 license.

相关化合物

结构式 名称/CAS号 全部文献
4-[4-[(5-硝基-2-呋喃基)亚甲基]-3,5-二氧代-1-吡唑烷基]苯甲酸乙酯 结构式 4-[4-[(5-硝基-2-呋喃基)亚甲基]-3,5-二氧代-1-吡唑烷基]苯甲酸乙酯
CAS:418805-02-4
放线菌酮 结构式 放线菌酮
CAS:66-81-9
4',6-二脒基-2-苯基吲哚二盐酸盐 结构式 4',6-二脒基-2-苯基吲哚二盐酸盐
CAS:28718-90-3
乳胞素 结构式 乳胞素
CAS:133343-34-7
蛋白酶体抑制剂 结构式 蛋白酶体抑制剂
CAS:133407-82-6